Effects of statin medication on mortality risk associated with type 2 diabetes in older persons: the population-based AGES-Reykjavik Study.
Cast your vote
You can rate an item by clicking the amount of stars they wish to award to this item.
When enough users have cast their vote on this item, the average rating will also be shown.
Your vote was cast
Thank you for your feedback
Thank you for your feedback
Harris, Tamara B
Launer, Lenore J
MetadataShow full item record
CitationBMJ Open 2011, 1(1):e000132
AbstractOBJECTIVE: To examine if the beneficial effect of statin medication on mortality seen in randomised clinical trials of type 2 diabetes applies equally to observational studies in the general population of older people. DESIGN: A prospective, population-based cohort study. SETTING: Reykjavik, Iceland. PARTICIPANTS: 5152 men and women from the Age, Gene/Environment Susceptibility-Reykjavik Study, mean age 77 years, range of 66-96 years. MAIN OUTCOME MEASURE: Cardiovascular and all-cause mortalities and the RR of dying according to statin use and history of coronary heart disease (CHD) in persons with type 2 diabetes and those without diabetes with a median follow-up time of 5.3 years, until end of 2009. RESULTS: The prevalence of type 2 diabetes was 12.4% of which 35% used statins. Statin use was associated with a 50% (95% CI 8% to 72%) lower cardiovascular mortality and 53% (29% to 68%) lower all-cause mortalities in persons with diabetes. For those without diabetes, statin use was associated with a 16% (-24% to 43%) lower cardiovascular and 30% (11% to 46%) lower all-cause mortalities. Persons with diabetes using statins had a comparable risk of cardiovascular and all-cause mortality to that of the general population without diabetes. The effect was independent of the level of glycaemic control. CONCLUSION: This observational study lends important support to existing data from randomised clinical trials. These data suggest that in the general population of older people with diabetes, statin medication markedly reduces the excess cardiovascular and all-cause mortality risk, irrespective of the presence or absence of coronary heart disease or glucose-lowering medication.
DescriptionTo access publisher full text version of this article. Please click on the hyperlink in Additional Links field.
RightsArchived with thanks to BMJ open
- Similar decline in mortality rate of older persons with and without type 2 diabetes between 1993 and 2004 the Icelandic population-based Reykjavik and AGES-Reykjavik cohort studies.
- Authors: Olafsdottir E, Aspelund T, Sigurdsson G, Benediktsson R, Thorsson B, Harris TB, Launer LJ, Eiriksdottir G, Gudnason V
- Issue date: 2013 Jan 15
- [Early life residency associated with the risk of developing type 2 diabetes - the population-based Reykjavík study].
- Authors: Olafsdottir E, Aspelund T, Torfadottir JE, Steingrimsdottir L, Sigurdsson G, Thorsson B, Benediktsson R, Eiriksdottir G, Valdimarsdottir UA, Gudnason V
- Issue date: 2012 Dec
- Migraine with aura and risk of cardiovascular and all cause mortality in men and women: prospective cohort study.
- Authors: Gudmundsson LS, Scher AI, Aspelund T, Eliasson JH, Johannsson M, Thorgeirsson G, Launer L, Gudnason V
- Issue date: 2010 Aug 24
- Statin use in the secondary prevention of coronary heart disease in primary care: cohort study and comparison of inclusion and outcome with patients in randomised trials.
- Authors: Wei L, Ebrahim S, Bartlett C, Davey PD, Sullivan FM, MacDonald TM
- Issue date: 2005 Apr 9
- Statin treatment in a cohort of 20 212 men and women in Norway according to cardiovascular risk factors and level of education.
- Authors: Selmer R, Sakshaug S, Skurtveit S, Furu K, Tverdal A
- Issue date: 2009 Mar